2026年11月3日星期二
M
Rekod Semesta
Berita Pantas Global
Anthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaEU steps up subsea cable buildout to Japan and South Korea— 日经 Nikkei AsiaJapan's Don Quijote drops refund fees for tourists to boost spending— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei Asia

[Correspondence] Unanswered questions from the NIMBLE trial

Sumber 柳叶刀 Lancet10 hari lalu
Ringkasan kandungan

Tuan Vu and colleagues reported that cemdisiran monotherapy (76·6% mean reduction from baseline in total complement haemolysis activity [CH50] inhibition) and…

Laman ini hanya menyediakan indeks tajuk dan ringkasan, kandungan penuh dan hak cipta adalah milik pihak penerbit asal, sila klik pautan asal untuk membaca.

Pergi ke artikel asal
Saluran berkaitan
Kesihatan
Kawasan berkaitan
United Kingdom
Bahasa teks asal
English
Nombor entri
health-c991f144

Comments 0 comments

No comments yet. Be the first.

[Correspondence] Unanswered questions from the NIMBLE trial · Rekod Semesta